Half‐life of exogenous growth hormone following suppression of endogenous growth hormone secretion with somatostatin in type I (insulin‐dependent) diabetes mellitus
- 17 March 1992
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 36 (3) , 255-263
- https://doi.org/10.1111/j.1365-2265.1992.tb01441.x
Abstract
Objective To estimate the half‐life of growth hormone In young adult patients with type I (insulin‐dependent) diabetes mellitus following bolus injection and prolonged exposure for the purpose of deconvolution analysis of plasma growth hormone profiles to determine growth hormone secretory rates design In the bolus study, an intravenous bolus injection of 100 mU of biosynthetic human growth hormone was given while endogenous growth hormone was suppressed by a continuous Infusion of somatostatin under three different glucose clamp conditions: normoglycae‐mla (5 mmol/l) with normoinsulinaemla (65 pmol/l); hyperglycaemia (12 mmol/l) with normofnsulinaemia; and normoglycaemia with hyperlnsullnaemia (360 pmol/l). In the infusion study, the effect of prolonged and repeated growth hormone exposure upon the growth hormone half‐life was estimated. Three pulses of 60 minutes growth hormone infusion (6 mU/kg/pulse) two hours apart under euglycaemic somatostatin suppression were applied. PATIENTS Six young adult patients with type I (insulin‐dependent) diabetes mellitus were studied in both the bolus and the infusion study results Mean GH half‐lives by mono‐exponential analysis were not significantly different remaining unaltered by the short‐term metabolic changes of hyperglycaemia and hyperinsullnaemla. Data were therefore pooled yielding an overall mean GH half‐life of 13·6 minutes (range 11·9–19·4). Applying a bl‐exponentlal model mean GH half‐lives were 3·1 minutes (range 2·5–5·9) for the rapid phase of distribution of the hormone and 13·4 minutes (range 9·6–16·9) for the decay of GH from the circulation The GH half‐life during the infusions studies did not vary with repeated exposure but was Significantly longer (mean half‐life of 25·7 minutes; range 19·4–37·1) than during the bolus studies (P > 0·001). conclusions The half‐life of exogenous r‐hGH is not affected by glucose or insulin concentrations but increases after prolonged GH exposure in young adults with type I (Insulin‐dependent) diabetes mellitusKeywords
This publication has 34 references indexed in Scilit:
- THE APPLICATION OF DECONVOLUTION ANALYSIS TO ELUCIDATE THE PULSATILE NATURE OF GROWTH HORMONE SECRETION USING A VARIABLE HALF-LIFE OF GROWTH HORMONEClinical Endocrinology, 1990
- Unbiased and Flexible Iterative Computer Program to Achieve Glucose ClampingDiabetes Care, 1989
- The role of growth hormone in diabetes mellitusJournal of Endocrinology, 1988
- Sample Preparation and Radioimmunoassay for Circulating Free and Antibody‐bound Insulin Concentrations in Insulin‐treated Diabetics: a Re‐evaluation of MethodsDiabetic Medicine, 1985
- THE HALF‐LIFE OF ENDOGENOUS INSULIN AND C‐PEPTIDE IN MAN ASSESSED BY SOMATOSTATIN SUPPRESSIONClinical Endocrinology, 1985
- Growth hormone kinetics in diabetic patientsDiabetes, 1975
- Daily production and metabolic clearance of growth hormone in juvenile diabetes mellitusDiabetologia, 1973
- Studies on the Metabolic Clearance Rate, Apparent Distribution Space and Plasma Half‐Disappearance Time of Unlabelled Human Growth Hormone in Normal Subjects and in Patients with Liver Disease, Renal Disease, Thyroid Disease and Diabetes MellitusEuropean Journal of Clinical Investigation, 1973
- Disappearance of Iodine-131-Iabelled Human Growth Hormone from the Plasma of Diabetic, non-Diabetic and Acromegalic SubjectsNature, 1966
- STUDIES ON HUMAN GROWTH HORMONE. II. THE PHYSIOLOGICAL DISPOSITION AND METABOLIC FATE OF HUMAN GROWTH HORMONE IN MAN*Journal of Clinical Investigation, 1962